H.U. Group Holdings Inc operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares H.U. Group Holdings Inc with three other
pharmaceutical manufacturers in Asia:
sales of 120.73 billion Japanese Yen [US$1.16 billion]
of which 95%
was Examination business),
Dr. Lal PathLabs Ltd
(13.30 billion Indian Rupees [US$179.73 million]
of which 100%
was ions), and
Falco Holdings Co Ltd
(43.19 billion Japanese Yen [US$414.58 million]
of which 61%
was Medical Test).
H.U. Group Holdings Inc reported sales of ¥188.71 billion (US$1.81 billion)
March of 2020.
increase of 4.0%
versus 2019, when the company's sales were ¥181.42 billion.
Despite this increase, sales are still
below the level achieved in 2018, when H.U. Group Holdings Inc
reported sales of ¥195.40 billion.
The sales level in 2020 was fairly close to the level five years ago: in 2015, H.U. Group Holdings Inc had sales
of ¥204.67 billion.
Sales of Clinical Examination saw an increase
that was more than double the company's growth rate: sales were up
8.7% in 2020, from
¥108.08 billion to ¥117.52 billion.
Not all segments of H.U. Group Holdings Inc experienced an increase in sales in 2020:
sales of Clinical Medical Check fell 11.7% to ¥40.09 billion.